Patient-reported outcomes from the phase 3 ADMIRAL trial in patients with FLT3-mutated relapsed/refractory AML

• Published in: Leukemia & lymphoma 2023-04, Vol.64 (5), p.938-950
• Main Authors: Ritchie, Ellen K., Cella, David, Fabbiano, Francesco, Pigneux, Arnaud, Kanda, Yoshinobu, Ivanescu, Cristina, Pandya, Bhavik J., Shah, Manasee V.
• Format: Article
• Language: English
• Subjects: Acute myeloid leukemia; fatigue; FLT3 inhibitor; health-related quality of life
• ISSN: 1042-8194; 1029-2403
• DOI: 10.1080/10428194.2023.2186731

Patient-reported outcomes (PROs) can inform treatment selection and assess treatment value in acute myeloid leukemia (AML). We evaluated PROs from the ADMIRAL trial (NCT02421939) in patients with FLT3-mutated relapsed/refractory (R/R) AML. PRO instruments consisted of Brief Fatigue Inventory (BFI), Functional Assessment of Cancer Therapy-Leukemia (FACT-Leu), Functional Assessment of Chronic Illness Therapy-Dyspnea Short Form (FACIT-Dys SF), EuroQoL 5-Dimension 5-Level (EQ-5D-5L), and leukemia treatment-specific symptom questionnaires. Clinically significant effects on fatigue were observed with gilteritinib during the first two treatment cycles. Shorter survival was associated with clinically significant worsening of BFI, FACT-Leu, FACIT-Dys SF, and EQ-5D-5L measures. Transplantation and transfusion independence in gilteritinib-arm patients were also associated with maintenance or improvement in PROs. Health-related quality of life remained stable in the gilteritinib arm. Hospitalization had a small but significant effect on patient-reported fatigue. Gilteritinib was associated with a favorable effect on fatigue and other PROs in patients with FLT3-mutated R/R AML.